Lisa Lancaster
- Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy resultsBy Ganesh Raghu, Mary Beth Scholand, Joao de Andrade, Lisa Lancaster, Jonathan Goldin, Seth Porter, Thomas Neff, Frank Valone and John StaufferGanesh Raghu1Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, United StatesMary Beth Scholand2Department of Medicine, Pulmonary Division, University of Utah, Salt Lake City, UT, United StatesJoao de Andrade3Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, AL, United StatesLisa Lancaster4Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, Nashville, TN, United StatesJonathan Goldin5Department of Radiology, David Geffen School of Medicine, Los Angeles, CA, United StatesSeth Porter6Clinical Development, FibroGen, Inc., San Francisco, CA, United StatesThomas Neff6Clinical Development, FibroGen, Inc., San Francisco, CA, United StatesFrank Valone6Clinical Development, FibroGen, Inc., San Francisco, CA, United StatesJohn Stauffer6Clinical Development, FibroGen, Inc., San Francisco, CA, United States
- Late-breaking abstract: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)By Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,Carlo Albera2Department of Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Z. Bradford3Research & Development, InterMune Inc., Brisbane, CA,Ulrich Costabel4Department of Pneumology, Ruhrlandklinik, Essen, GermanyRoland M. du Bois5Respiratory Medicine, Imperial College, London, United KingdomRobert S. Fishman3Research & Development, InterMune Inc., Brisbane, CA,Ian Glaspole6Interstitial Lung Disease, Alfred Hospital, Melbourne, AustraliaMarilyn K. Glassberg7Pulmonology, University of Miami Miller School of Medicine, Miami, FL,Lisa Lancaster8Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN,David Lederer9Department of Clinical Medicine, Columbia University Medical Center, New York, NY,Jonathan A. Leff3Research & Development, InterMune Inc., Brisbane, CA,Steven D. Nathan10Advanced Lung Disease & Transplant Program, Inova Fairfax Hospital, Falls Church, VA,Carlos A. Pereira11Department of Medicine, Paulista School of Medicine, São Paulo, BrazilJeffrey J. Swigris12Department of Medicine, National Jewish Health, Denver, CO,Dominique Valeyre13Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobginy, FranceTalmadge E. King Jr14Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA,
- Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)By Talmadge King, Williamson Bradford, Socorro Castro-Bernardini, Elizabeth Fagan, Ian Glaspole, Marilyn Glassberg, Eduard Gorina, Peter Hopkins, David Kardatzke, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, Steven Sahn, Robert Sussman, Jeffrey Swigris and Paul NobleTalmadge King1Medicine, University of California, San Francisco, San Francisco, CA,Williamson Bradford2Clinical Research, Intermune Inc, Brisbane, CA,Socorro Castro-Bernardini3Neumocare, Clínica San Borja, Lima, PeruElizabeth Fagan2Clinical Research, Intermune Inc, Brisbane, CA,Ian Glaspole4Medicine, Alfred Hospital, Melbourne, AustraliaMarilyn Glassberg5Medicine, University of Miami Miller School of Medicine, Miami, FL,Eduard Gorina2Clinical Research, Intermune Inc, Brisbane, CA,Peter Hopkins6Medicine, Prince Charles Hospital, Brisbane, QLD, AustraliaDavid Kardatzke2Clinical Research, Intermune Inc, Brisbane, CA,Lisa Lancaster7Medicine, Vanderbilt University Medical Center, Nashville, TN,David Lederer8Medicine, Columbia University Medical Center, New York, NY,Steven Nathan9Medicine, Inova Fairfax Hospital, Falls Church, VA,Carlos Pereira10Medicine, Paulista School of Medicine, Federal University of Sao Paulo, Sao Paolo, BrazilSteven Sahn11Medicine, Medical University of South Carolina, Charleston, SC,Robert Sussman12Medicine, Pulmonary and Allergy Associates, Summit, NJ,Jeffrey Swigris13Medicine, National Jewish Health, Denver, CO,Paul Noble14Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,
- CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumabBy Ganesh Raghu, Fernando J. Martinez, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Athol U. Wells, Lisa Lancaster, Kevin F. Gibson, Tarik Haddad, Prasheen Agarwal, Michael Mack, Bidisha Dasgupta, Ivo P. Nnane, Susan K. Flavin and Elliot S. BarnathanArticle | Published in 2015 in European Respiratory JournalGanesh Raghu1Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA, USAFernando J. Martinez2Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USAKevin K. Brown3Department of Medicine, National Jewish Health, Denver, CO, USAUlrich Costabel4Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, GermanyVincent Cottin5National Reference Centre, Department of Respiratory Medicine, Claude Bernard Lyon 1 University, Hospices Civils de Lyon, Lyon, FranceAthol U. Wells6Royal Brompton Hospital, Imperial College London NHS Healthcare Trust, London, UKLisa Lancaster7Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN, USAKevin F. Gibson8Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USATarik Haddad9New Lung Associates, Tampa, FL, USAPrasheen Agarwal10Janssen Research & Development LLC, Spring House, PA, USAMichael Mack10Janssen Research & Development LLC, Spring House, PA, USABidisha Dasgupta10Janssen Research & Development LLC, Spring House, PA, USAIvo P. Nnane10Janssen Research & Development LLC, Spring House, PA, USASusan K. Flavin10Janssen Research & Development LLC, Spring House, PA, USAElliot S. Barnathan10Janssen Research & Development LLC, Spring House, PA, USA
- Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)By Steven Nathan, Carlo Albera, Williamson Bradford, Ulrich Costabel, Roland Du Bois, Elizabeth Fagan, Robert Fishman, Ian Glaspole, Marilyn Glassberg, Kenneth Glasscock, Lisa Lancaster, David Lederer, Zhengning Lin, Carlos Pereira, Jeffrey Swigris, Dominique Valeyre, Paul Noble and Athol WellsSteven Nathan1Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, United StatesCarlo Albera2Department of Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Bradford3Research and Development, Intermune Inc, Brisbane, CA United StatesUlrich Costabel4Department of Pneumology, Ruhrlandklinik, Essen, GermanyRoland Du Bois5Department of Respiratory Medicine, Imperial College, London, United KingdomElizabeth Fagan3Research and Development, Intermune Inc, Brisbane, CA United StatesRobert Fishman3Research and Development, Intermune Inc, Brisbane, CA United StatesIan Glaspole6Department of Immunology, Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn Glassberg7Department of Pulmonology, University of Miami Miller School of Medicine, Miami, United StatesKenneth Glasscock3Research and Development, Intermune Inc, Brisbane, CA United StatesLisa Lancaster8Department of Medicine, Vanderbilt University Medical Center, Nashville, United StatesDavid Lederer9Department of Clinical Medicine, Columbia University Medical Center, New York, United StatesZhengning Lin3Research and Development, Intermune Inc, Brisbane, CA United StatesCarlos Pereira10Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey Swigris11Department of Medicine, National Jewish Health, Denver, United StatesDominique Valeyre12Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FrancePaul Noble13Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United StatesAthol Wells14Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
- CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumabBy Ganesh Raghu, Fernando J. Martinez, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Athol U. Wells, Lisa Lancaster, Kevin F. Gibson, Tarik Haddad, Prasheen Agarwal, Michael Mack, Bidisha Dasgupta, Ivo P. Nnane, Susan K. Flavin and Elliot S. BarnathanGanesh Raghu1Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA, USAFernando J. Martinez2Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USAKevin K. Brown3Department of Medicine, National Jewish Health, Denver, CO, USAUlrich Costabel4Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, GermanyVincent Cottin5National Reference Centre, Department of Respiratory Medicine, Claude Bernard Lyon 1 University, Hospices Civils de Lyon, Lyon, FranceAthol U. Wells6Royal Brompton Hospital, Imperial College London NHS Healthcare Trust, London, UKLisa Lancaster7Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN, USAKevin F. Gibson8Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USATarik Haddad9New Lung Associates, Tampa, FL, USAPrasheen Agarwal10Janssen Research & Development LLC, Spring House, PA, USAMichael Mack10Janssen Research & Development LLC, Spring House, PA, USABidisha Dasgupta10Janssen Research & Development LLC, Spring House, PA, USAIvo P. Nnane10Janssen Research & Development LLC, Spring House, PA, USASusan K. Flavin10Janssen Research & Development LLC, Spring House, PA, USAElliot S. Barnathan10Janssen Research & Development LLC, Spring House, PA, USA
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingArticle | Published in 2015 in European Respiratory JournalPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
- FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPFBy Ganesh Raghu, Mary Beth Scholand, João de Andrade, Lisa Lancaster, Yolanda Mageto, Jonathan Goldin, Kevin K. Brown, Kevin R. Flaherty, Mark Wencel, Jack Wanger, Thomas Neff, Frank Valone, John Stauffer and Seth PorterArticle | Published in 2016 in European Respiratory JournalGanesh Raghu1University of Washington, Seattle, WA, USAMary Beth Scholand2University of Utah, Salt Lake City, UT, USAJoão de Andrade3University of Alabama at Birmingham, Birmingham, AL, USALisa Lancaster4Vanderbilt University, Nashville, TN, USAYolanda Mageto5University of Vermont, Burlington, VT, USAJonathan Goldin6David Geffen School of Medicine, Los Angeles, CA, USAKevin K. Brown7National Jewish Health, Denver, CO, USAKevin R. Flaherty8University of Michigan Health System, USAMark Wencel9Via Christi Clinic, Wichita, KS, USAJack Wanger10Pulmonary Function and Clinical Trial Consultant, Rochester, MN, USAThomas Neff11FibroGen, Inc., San Francisco, CA, USAFrank Valone11FibroGen, Inc., San Francisco, CA, USAJohn Stauffer11FibroGen, Inc., San Francisco, CA, USASeth Porter11FibroGen, Inc., San Francisco, CA, USA
- FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosisBy Ganesh Raghu, Mary Beth Scholand, João de Andrade, Lisa Lancaster, Yolanda Mageto, Jonathan Goldin, Kevin K. Brown, Kevin R. Flaherty, Mark Wencel, Jack Wanger, Thomas Neff, Frank Valone, John Stauffer and Seth PorterGanesh Raghu1University of Washington, Seattle, WA, USAMary Beth Scholand2University of Utah, Salt Lake City, UT, USAJoão de Andrade3University of Alabama at Birmingham, Birmingham, AL, USALisa Lancaster4Vanderbilt University, Nashville, TN, USAYolanda Mageto5University of Vermont, Burlington, VT, USAJonathan Goldin6David Geffen School of Medicine, Los Angeles, CA, USAKevin K. Brown7National Jewish Health, Denver, CO, USAKevin R. Flaherty8University of Michigan Health System, USAMark Wencel9Via Christi Clinic, Wichita, KS, USAJack Wanger10Pulmonary Function and Clinical Trial Consultant, Rochester, MN, USAThomas Neff11FibroGen, Inc., San Francisco, CA, USAFrank Valone11FibroGen, Inc., San Francisco, CA, USAJohn Stauffer11FibroGen, Inc., San Francisco, CA, USASeth Porter11FibroGen, Inc., San Francisco, CA, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
